- Home
- PLRX vs SLS Comparison
PLRX vs SLS Comparison
Compare PLRX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- SLS
- Stock Information
- Founded
- PLRX 2015
- SLS 2012
- Country
- PLRX United States
- SLS United States
- Employees
- PLRX N/A
- SLS N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- SLS Health Care
- Exchange
- PLRX Nasdaq
- SLS Nasdaq
- Market Cap
- PLRX 90.9M
- SLS 89.6M
- IPO Year
- PLRX 2020
- SLS N/A
- Fundamental
- Price
- PLRX $1.41
- SLS $1.56
- Analyst Decision
- PLRX Hold
- SLS
- Analyst Count
- PLRX 10
- SLS 0
- Target Price
- PLRX $9.79
- SLS N/A
- AVG Volume (30 Days)
- PLRX 726.8K
- SLS 2.0M
- Earning Date
- PLRX 05-08-2025
- SLS 05-20-2025
- Dividend Yield
- PLRX N/A
- SLS N/A
- EPS Growth
- PLRX N/A
- SLS N/A
- EPS
- PLRX N/A
- SLS N/A
- Revenue
- PLRX N/A
- SLS N/A
- Revenue This Year
- PLRX N/A
- SLS N/A
- Revenue Next Year
- PLRX N/A
- SLS N/A
- P/E Ratio
- PLRX N/A
- SLS N/A
- Revenue Growth
- PLRX N/A
- SLS N/A
- 52 Week Low
- PLRX $1.10
- SLS $0.77
- 52 Week High
- PLRX $16.52
- SLS $1.85
- Technical
- Relative Strength Index (RSI)
- PLRX 39.44
- SLS 61.26
- Support Level
- PLRX $1.36
- SLS $1.60
- Resistance Level
- PLRX $1.72
- SLS $1.85
- Average True Range (ATR)
- PLRX 0.11
- SLS 0.13
- MACD
- PLRX 0.04
- SLS 0.02
- Stochastic Oscillator
- PLRX 13.89
- SLS 50.85
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.